Summary
Congestive heart failure (CHF) is a syndrome characterized by increased levels of angiotensin II (Ang II) and endothelin-1 (ET-1). In vitro, Ang II stimulates ET-1 release. The purpose of this study was to assess the effect of a single dose of an angiotensin-converting enzyme inhibitor (ACEI) captopril versus placebo on plasma endothelin concentration in human congestive heart failure. Captopril (25 mg, given orally) was compared with placebo in a group of 20 patients with systolic dysfunction in a double-blind randomized study. Plasma irET concentration was significantly increased in CHF patients compared with normal subjects (5.59 pg/ml±0.35 vs. 3.58 pg/ml±0.99, p<0.0002). Despite the decrease in systolic blood pressure and the increase in plasma renin activity, suggesting a significant blockade of the renin-angiotensin system, no difference in plasma irET-1 was observed between captopril and placebo. Our results suggest that captopril does not acutely influence irET-1 plasma concentration in human CHF. These data do not support the hypothesis that the acute vasodilator effect of a single dose of 25 mg of captopril given orally involves modulation of the increased plasma concentration of endothelin observed in CHF.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–415.
Grenier O, Komajda M, Maistre G, et al. Endothelin plasma concentration is increased in chronic congestive heart failure (abstr). Circulation 1990;82:III-381.
McMurray J, Ray S, Abdullah I, Dargie H, Morton J. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374–1379.
Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580–1586.
Teicholz LE, Kreulent T, Herman MV, Gorlin R. Problems in echocardiographic volume determination: Echocardiographic-angiographic determination, the presence or absence of asynergy. Am J Cardiol 1976;37:7–11.
Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504–509.
Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in cultured endothelial cells. Hypertension 1992;19:753–757.
Yoshida H, Nakamura M. Inhibition by angiotensin converting enzyme inhibitors of endothelin secretion from cultured human endothelial cells. Life Sci 1992;50:195–200.
Tohmo H, Karanko M, Scheini M, et al. Enalapril premedication attenuates the blood pressure response to tracheal intubation and stabilizes postoperative blood pressure after controlled hypotension with sodium nitroprusside in neurovascular patients. J Neurosurg Anesthesiol 1993;5:13–21.
Townend J, Doran J, Jones S, Davies M. Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure. Int J Cardiol 1994;43:299–304.
Margulies KB, Hildebrand FL, Lerman A, Perrella MA, Burnett JC. Increased endothelin in experimental heart failure. Circulation 1990;82:2226–2230.
Goto K, Yanagisawa M, Kimura S, Masaki T. Cardiovascular effect of endothelin. Jpn Circ J 1992;56:162–169.
Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127:607–612.
Good JM, Nihoyannopoulos P, Ghatei MA, et al. Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? Eur Heart J 1994;15:1634–1640.
Okunishi H, Miyasaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Comm 1987;149:1186–1192.
Mortensen LH, Fink GD. Captopril prevents chronic hypertension produced by infusion of endothelin-1 in rats. Hypertension 1992;19:676–680.
Uemasu J, Matsumoto H, Kitano M, Kawasaki H. Suppression of plasma endothelin-1 level by α-human atrial natriuretic peptide and angiotensin converting enzyme inhibition in normal men. Life Sc 1993;53:969–974.
Clavell AL, Mattingly MM, Nir A, Aarhus LL, Heublein DM, Burnett JC. Angiotensin converting enzyme inhibition modulates circulating and tissue endothelin activity in experimental heart failure (abstr). Circulation 1994;90:I452.
Galatius-Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunsø S, Kastrup J. Endothelin in heart failure normalizes during treatment with the angiotensin converting enzyme inhibitor fosinopril. Circulation 1995;92(Suppl 1):I208.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grenier, O., Pousset, F., Isnard, R. et al. Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure. Cardiovasc Drug Ther 10, 561–565 (1996). https://doi.org/10.1007/BF00050997
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00050997